Related Experiment Video
Updated: May 17, 2026
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Prospects and challenges for the development of new therapies for Ewing sarcoma
Patrick J Grohar1, Lee J Helman
1Department of Pediatrics, Vanderbilt University School of Medicine and the Monroe Carrell Junior Children's Hospital, Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 397, Nashville, TN 37232-6310, USA. patrick.grohar@vanderbilt.edu
Abstract:
The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has improved through the development of intense multimodal therapy over the past several decades. Unfortunately, patients with recurrent or metastatic disease continue to have a poor prognosis. Therefore, a number of complementary approaches are being developed in both the preclinical and clinical arenas to improve these outcomes. In this review, we will discuss efforts to directly target the biologic drivers of this disease and relate these efforts to the experience with several different agents both in the clinic and under development. We will review the data for compounds that have shown excellent activity in the clinic, such as the camptothecins, and summarize the biological data that supports this activity. In addition, we will review the clinical experience with IGF1 targeted agents, ET-743 and epigenetically targeted therapies, the substantial amount of literature that supports their activity in Ewing sarcoma and the challenges remaining translating these therapies to the clinic. Finally, we will highlight recent work aimed at directly targeting the EWS-FLI1 transcription factor with small molecules in Ewing tumors.
Insights
New therapies are being developed to combat recurrent or metastatic Ewing sarcoma (ES), a rare childhood bone cancer. Research focuses on targeting the disease's biological drivers, including EWS-FLI1, to improve patient outcomes.
Area of Science:
- Pediatric Oncology
- Cancer Biology
- Translational Research
Background:
- Ewing sarcoma (ES) is the second most common pediatric malignant bone tumor.
- Localized ES prognosis has improved with multimodal therapy, but recurrent/metastatic disease remains challenging.
- Novel therapeutic strategies are crucial for improving outcomes in advanced ES.
Purpose of the Study:
- To review current and emerging therapeutic strategies targeting the biologic drivers of Ewing sarcoma.
- To discuss the clinical experience and preclinical data supporting novel agents in ES treatment.
- To highlight recent advancements in targeting EWS-FLI1 in Ewing tumors.
Main Methods:
- Review of preclinical and clinical data on targeted therapies for Ewing sarcoma.
- Analysis of agents including camptothecins, IGF1 targeted agents, ET-743, and epigenetic therapies.
- Summary of research on small molecules targeting the EWS-FLI1 transcription factor.
Main Results:
- Camptothecins have demonstrated significant clinical activity in Ewing sarcoma.
- IGF1 targeted agents, ET-743, and epigenetic therapies show promise, with substantial supporting literature.
- Targeting the EWS-FLI1 transcription factor with small molecules is an active area of research.
Conclusions:
- Despite progress, significant challenges remain in translating novel therapies to the clinic for Ewing sarcoma.
- Targeting specific molecular pathways and the EWS-FLI1 fusion protein offers potential for improved Ewing sarcoma treatment.
- Continued research into complementary approaches is essential for overcoming poor prognoses in recurrent or metastatic disease.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle